Industry Briefs: Apr. 16, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. Read More

Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe. Read More

Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate. Read More

Pharmatek has added to its liquid encapsulation capabilities. Read More

Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.

Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology. Read More

Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly. Read More

People News

Hospira has named John B. Elliot senior vice-president of operations. Read More

Penn Pharma has appointed Jerome Detreille as senior director of new business development. Read More

Michael A. Griffith has been appointed to Repligen’s board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here